Freddy Jimenez

Learn More
The US Food and Drug Administration's ('FDA' or the 'Agency') current regulatory framework for drug promotion, by significantly restricting the ability of drug manufacturers to communicate important, accurate, up-to-date scientific information about their products that is truthful and non-misleading, runs afoul of the First Amendment and actually runs(More)
At the outset, we wish to thank Joan H. Krause 1 and Patricia J. Zettler 2 for their thoughtful commentaries on our article, 'Back to First Principles: A New Model for the Regulation of Drug Promotion'. Our New Model is intended as an 'initial' proposal for a modern, sustainable regulatory framework that comprehensively addresses drug promotion while(More)
Nowadays, ageing related diseases represent one of the most relevant challenges for developed countries. The use of healthcare remote technology may allow reducing most of the management of the chronic diseases meanwhile it may also contribute to the improvement of elderly people's quality of life. Unfortunately, despite the advent of Internet of things and(More)
  • 1